Cullgen

Cullgen is a biotechnology company focused on developing small molecule therapeutics, applying its ubitquitin-mediated, small molecule-inducted target elimination (uSMITE) plaftorm, for the potential treatment of cancer and immune diseases.By December 2022, GNI Group had hold the 36% of the company's shares.In May 2023, the company raised USD 40 million in new financing. It included USD 35 million in series C financing round led by AstraZeneca-CICC Venture Capital Partnership (AZ-CICC), Sincere Capital, Voyagers Capital, Wuxi Capital Group (subject to pending ODI approval) and existing shareholder GNI Group, well as USD 5 million from GNI Group following its election to exercise its outstanding warrants for the company stock,.In February 2021, the company closed USD 50 million series B financing investment.In April 2019, the company had received a USD 16 million series A financing.In March 2018, the company announced a series seed financing of up to USD 15